References

Cognitive decline in Parkinson disease

10.1038/nrneurol.2017.27 · 2017 · External reference

A systematic review of prevalence studies of dementia in Parkinson's disease

10.1002/mds.20527 · 2005 · External reference

Increased AGE-RAGE axis stress in methamphetamine abuse and methamphetamine-induced psychosis: associations with oxidative stress and increased atherogenicity

10.1111/adb.13333 · 2023 · External reference

CSF Aβ42 predicts early-onset dementia in Parkinson disease

10.1212/wnl.0000000000000425 · 2014 · External reference

Functions of p38 MAP Kinases in the Central Nervous System

10.3389/fnmol.2020.570586 · 2020 · External reference

The p38(MAPK)-MK2 Signaling Axis as a Critical Link Between Inflammation and Synaptic Transmission

10.3389/fcell.2021.635636 · 2021 · External reference

Parkinson's disease

10.1016/s0140-6736(21)00218-x · 2021 · External reference

Brain-first versus gut-first parkinson's disease: a hypothesis

2019 · External reference

Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild alzheimer's disease

10.14283/jpad.2018.18 · 2018 · External reference

Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature

10.1161/hypertensionaha.112.195511 · 2012 · External reference

Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway

10.1016/j.neuroscience.2013.10.056 · 2014 · External reference

P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model

10.1172/jci25247 · 2005 · External reference

Lewy body cortical involvement may not always predict dementia in Parkinson's disease

10.1136/jnnp.74.7.852 · 2003 · External reference

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

10.1002/mds.22594 · 2009 · External reference

10.1093/brain/awr031

10.1093/brain/awr031 · External reference

Oxidative stress in Alzheimer's disease hippocampus: a topographical study

10.1016/j.jns.2010.08.029 · 2010 · External reference

Cerebral Hypoxia-Induced Molecular Alterations and Their Impact on the Physiology of Neurons and Dendritic Spines: A Comprehensive Review

10.1007/s10571-024-01491-4 · 2024 · External reference

Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease

10.1016/j.biopsych.2008.07.024 · 2009 · External reference

Evidence of oxidative stress in the neocortex in incidental Lewy body disease

10.1097/01.jnen.0000179050.54522.5a · 2005 · External reference

RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

10.1038/nm890 · 2003 · External reference

A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease

10.1172/jci58642 · 2012 · External reference

LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms

10.1016/j.neuron.2004.07.017 · 2004 · External reference

The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis

10.1016/j.immuni.2018.08.016 · 2018 · External reference

The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration

10.4172/2161-0460.1000421 · 2018 · External reference

Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease

10.1016/j.physbeh.2025.115034 · 2025 · External reference

RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease

10.1007/s00401-006-0115-3 · 2006 · External reference

Pathophysiology of RAGE in inflammatory diseases

10.3389/fimmu.2022.931473 · 2022 · External reference

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia

10.1001/archneur.62.11.1734 · 2005 · External reference

The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes

10.1016/j.redox.2021.101958 · 2021 · External reference

HMGB1/RAGE signaling mediates the activation of microglia and participates in depressive-like behaviors and cognitive deficits in rats after ischemia-reperfusion

10.1016/j.bbr.2025.115662 · 2025 · External reference

RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease

10.1096/fj.09-139634 · 2010 · External reference

CNS infections, sepsis and risk of Parkinson's disease

10.1093/ije/dys052 · 2012 · External reference

The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: A role for the NLRP3 inflammasome

10.1016/j.bbi.2015.10.009 · 2016 · External reference

Metabolic derangements contribute to reduced sRAGE isoforms in subjects with Alzheimer's disease

10.1155/2018/2061376 · 2018 · External reference

Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease

10.1212/wnl.0000000000000364 · 2014 · External reference

Targeting the RAGE–RIPK1 binding site attenuates diabetes-associated cognitive deficits

10.1186/s12974-025-03489-1 · 2025 · External reference

Traumatic brain injury in later life increases risk for Parkinson disease

10.1002/ana.24396 · 2015 · External reference

Receptor for advanced glycation end products mediates sepsis-triggered amyloid-beta accumulation, Tau phosphorylation, and cognitive impairment

10.1074/jbc.m117.786756 · 2018 · External reference

Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation

10.1038/s41598-017-09257-3 · 2017 · External reference

RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions

2023 · External reference

A review of behavioral methods for the evaluation of cognitive performance in animal models: Current techniques and links to human cognition

10.1016/j.physbeh.2021.113652 · 2022 · External reference

Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment

2008 · External reference

Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice

10.1016/s0002-9440(10)61723-3 · 2001 · External reference

AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation

10.1016/j.neurobiolaging.2010.05.026 · 2012 · External reference

Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade

10.3233/jad-179935 · 2019 · External reference

Dementia in Parkinson's disease

10.1016/j.jns.2017.01.012 · 2017 · External reference

Structural Neuroimaging Markers of Cognitive Decline in Parkinson's Disease

2016 · External reference

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

10.1016/s0092-8674(00)80801-6 · 1999 · External reference

A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria

10.1016/s1474-4422(23)00404-0 · 2024 · External reference

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

10.1074/jbc.270.43.25752 · 1995 · External reference

Hypertension and Diagnosis of Parkinson's Disease: A Meta-Analysis of Cohort Studies

10.3389/fneur.2018.00162 · 2018 · External reference

Influence of ADAM10 polymorphisms on plasma level of soluble receptor for advanced glycation end products and the association with Alzheimer's disease risk

10.3389/fgene.2018.00540 · 2018 · External reference

Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson's disease pathogenesis

10.1007/s00401-018-1907-y · 2019 · External reference

A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β

10.1126/scitranslmed.3003748 · 2012 · External reference

Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures

10.1016/j.nbd.2013.03.006 · 2013 · External reference

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

10.1038/nrn3549 · 2013 · External reference

Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

10.3390/ijms25010498 · 2023 · External reference

Pathogenic role of RAGE in tau transmission and memory deficits

10.1016/j.biopsych.2022.10.015 · 2023 · External reference

Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice

10.1016/j.neurobiolaging.2006.06.019 · 2007 · External reference

Receptors for Advanced Glycation End Products (RAGE): Promising Targets Aiming at the Treatment of Neurodegenerative Conditions

10.2174/1570159x20666220922153903 · 2023 · External reference

Disruption of blood-brain barrier in Alzheimer disease pathogenesis

10.4161/tisb.23993 · 2013 · External reference

Imaging changes associated with cognitive abnormalities in Parkinson's disease

10.1007/s00429-014-0785-x · 2015 · External reference

Differential Gray Matter Vulnerability in the 1 Year Following a Clinically Isolated Syndrome

10.3389/fneur.2018.00824 · 2018 · External reference

Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition

10.1007/s11910-019-1006-z · 2019 · External reference

Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer's disease brain

10.1016/j.neurobiolaging.2014.09.025 · 2015 · External reference

Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition

10.1007/s10548-018-0675-2 · 2019 · External reference

Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy

10.1186/s40035-024-00430-z · 2024 · External reference

Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging

10.1016/j.parkreldis.2020.11.011 · 2021 · External reference

CRISPR/Cas9 Edited sRAGE-MSCs Protect Neuronal Death in Parkinsons Disease Model

10.15283/ijsc18110 · 2019 · External reference

RAGE/AP-1/OTR signaling pathway in rat hippocampus DG involved in CUS induced depressive-like behaviors

10.1016/j.bbr.2025.115540 · 2025 · External reference

Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer's disease

10.1016/j.jocn.2012.06.005 · 2013 · External reference

Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response

10.1172/jci200418704 · 2004 · External reference

Amyloid-β and Parkinson's disease

10.1007/s00415-018-9100-8 · 2019 · External reference

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI

10.1002/mds.23823 · 2011 · External reference

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

10.1002/mds.24893 · 2012 · External reference

Interaction of RAGE with alpha-synuclein fibrils mediates inflammatory response of microglia

10.1016/j.celrep.2022.111401 · 2022 · External reference

Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease

2021 · External reference

The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress

10.2174/0115680266320808240709061445 · 2024 · External reference

Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses

10.1038/s41531-024-00823-x · 2024 · External reference

High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products

10.1016/j.expneurol.2011.08.012 · 2011 · External reference

A novel role for the Receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricular Zone

10.1016/j.mcn.2010.06.005 · 2010 · External reference

Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease

10.1016/j.brainres.2008.06.124 · 2008 · External reference

RAGE signaling is required for AMPA receptor dysfunction in the hippocampus of hyperglycemic mice

10.1016/j.physbeh.2020.113255 · 2021 · External reference

The HMGB1 receptor RAGE mediates ischemic brain damage

10.1523/jneurosci.2435-08.2008 · 2008 · External reference

Crosslinking of α-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation?

10.1016/s0891-0618(00)00096-x · 2000 · External reference

Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta-analysis of controlled studies

10.1111/eci.14232 · 2024 · External reference

Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies

10.1016/j.neurobiolaging.2014.07.005 · 2015 · External reference

Case-control study of hypertension and Parkinson's disease

10.1038/s41531-021-00202-w · 2021 · External reference

Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases

10.1097/mib.0000000000000667 · 2016 · External reference

Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction

10.1016/j.neuropharm.2014.05.007 · 2014 · External reference

MAPK, β-amyloid and synaptic dysfunction: the role of RAGE

10.1586/ern.09.107 · 2009 · External reference

Aβ-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE

10.3233/jad-2009-1045 · 2009 · External reference

RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment

10.1523/jneurosci.0141-14.2014 · 2014 · External reference

Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction

10.1523/jneurosci.0204-08.2008 · 2008 · External reference

Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's Disease

10.3389/fnagi.2020.00156 · 2020 · External reference

α-synuclein pathology does not predict extrapyramidal symptoms or dementia

10.1002/ana.20321 · 2005 · External reference

HMGB1-mediated neuroinflammatory responses in brain injuries: potential mechanisms and therapeutic opportunities

10.3390/ijms21134609 · 2020 · External reference

Increased alpha-synuclein and neuroinflammation in the substantia nigra triggered by systemic inflammation are reversed by targeted inhibition of the receptor for advanced glycation end products (RAGE)

10.1111/jnc.15956 · 2024 · External reference

Microglial priming in neurodegenerative disease

10.1038/nrneurol.2014.38 · 2014 · External reference

Microglia in neurodegenerative disease

10.1038/nrneurol.2010.17 · 2010 · External reference

Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice--a longitudinal study

10.1371/journal.pone.0019567 · 2011 · External reference

RAGE expression and ROS generation in neurons: differentiation versus damage

10.1155/2016/9348651 · 2016 · External reference

The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways

10.1096/fj.202002136r · 2020 · External reference

A review of methods used to study cognitive deficits in Parkinson's disease

10.1179/1743132812y.0000000118 · 2013 · External reference

Progression of Cognitive Decline in Parkinson's Disease

2018 · External reference

Enteric glia in homeostasis and disease: From fundamental biology to human pathology

10.1016/j.isci.2021.102863 · 2021 · External reference

Parkinson disease with dementia: comparing patients with and without Alzheimer pathology

10.1097/wad.0b013e31819c5ef4 · 2009 · External reference

PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease

10.1097/wad.0b013e318204b550 · 2011 · External reference

Classifying neurocognitive disorders: the DSM-5 approach

10.1038/nrneurol.2014.181 · 2014 · External reference

Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice

10.1371/journal.pone.0008309 · 2009 · External reference

In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

10.1016/j.nbd.2016.02.018 · 2016 · External reference

An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aβ42 and an APOE ε4 allele

10.1016/j.nbd.2019.02.023 · 2019 · External reference

Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia

10.1007/s12031-016-0837-1 · 2016 · External reference

Anti-RAGE antibody attenuates isoflurane-induced cognitive dysfunction in aged rats

10.1016/j.bbr.2017.01.012 · 2017 · External reference

Neuroimaging and cognition in Parkinson's disease dementia

10.1111/j.1750-3639.2009.00368.x · 2010 · External reference

Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies

2019 · External reference

Extracellular HSP70 Activates ERK1/2, NF-kappa B and Pro-Inflammatory Gene Transcription Through Binding with RAGE in A549 Human Lung Cancer Cells

10.1159/000480213 · 2017 · External reference

Early-stage Parkinson's disease detection using multimodal brain-body biomarkers from fNIRS and IMU data

10.1016/j.compbiomed.2025.111096 · 2025 · External reference

Assessing behavior and cognition in rodents, nonhuman primates, and humans: where are the limits of translation?

10.31887/dcns.2019.21.3/mrossner · 2019 · External reference

The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM

10.1016/j.bbi.2018.07.017 · 2018 · External reference

Hospital-treated infections in early- and mid-life and risk of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden

10.1371/journal.pmed.1004092 · 2022 · External reference

Vagotomy and subsequent risk of Parkinson's disease

10.1002/ana.24448 · 2015 · External reference

Clearance systems in the brain-implications for Alzheimer disease

10.1038/nrneurol.2015.119 · 2015 · External reference

The impact of neuroinflammation on neuronal integrity

10.1111/imr.13419 · 2024 · External reference

Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses

10.1038/s41531-025-01159-w · 2025 · External reference

Glycation in Parkinson's disease and Alzheimer's disease

10.1002/mds.26566 · 2016 · External reference

Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies

10.1093/brain/awx056 · 2017 · External reference

RAGE does not affect amyloid pathology in transgenic ArcAβ mice

10.1159/000261723 · 2009 · External reference

Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice

10.3233/jad-170483 · 2018 · External reference

Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models

10.3389/fgene.2014.00088 · 2014 · External reference

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort

10.1136/jnnp-2013-305277 · 2013 · External reference

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease

10.1001/jamaneurol.2017.3713 · 2018 · External reference

Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias

10.1016/j.cpet.2017.02.005 · 2017 · External reference

Septic shock is associated with receptor for advanced glycation end products ligation of LPS

10.4049/jimmunol.1002253 · 2011 · External reference

Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice

10.1038/s42003-019-0325-6 · 2019 · External reference

RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease

10.1038/382685a0 · 1996 · External reference

RAGE Signaling pathway in hippocampus dentate gyrus involved in GLT-1 decrease induced by chronic unpredictable stress in rats

10.1016/j.brainresbull.2020.06.020 · 2020 · External reference

Targeting Inflammation Driven by HMGB1

10.3389/fimmu.2020.00484 · 2020 · External reference

MD-2 is required for disulfide HMGB1-dependent TLR4 signaling

10.1084/jem.20141318 · 2015 · External reference

RAGE in circulating immune cells is fundamental for hippocampal inflammation and cognitive decline in a mouse model of latent chronic inflammation

10.1016/j.bbi.2023.12.022 · 2024 · External reference

Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease

10.1007/s00018-009-0121-4 · 2009 · External reference

Inhibitor Development for α-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology

10.1021/jacs.4c08869 · 2024 · External reference

Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance

10.1038/nn.4025 · 2015 · External reference

Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia-derived neuroinflammation

10.1111/cns.14449 · 2024 · External reference

Endothelial RAGE exacerbates acute postischaemic cardiac inflammation

10.1160/th15-11-0898 · 2016 · External reference